Member Posts > Cardiol Therapeutics' CRD-38: Advancing Heart Failure Treatment with Groundbreaking Science
Cardiol Therapeutics is taking a bold step toward solving one of cardiology's toughest challenges: treating HFpEF effectively. Their investigational drug, CRD-38, is showing unprecedented promise in pre-clinical studies.
The study, published in The Journal of the American College of Cardiology: Basic to Translational Science, highlights CRD-38's ability to preserve heart function, reduce harmful inflammation, and improve mitochondrial efficiency.
Study Highlights
• Increased Ejection Fraction: Improving heart function and circulation.
• Reduced Fibrosis: Preventing heart stiffening and scarring.
• Suppressed Inflammation: Blocking pro-inflammatory pathways.
• Mitochondrial Protection: Supporting energy production in heart cells.
With clinical trials on the horizon, CRD-38 could emerge as a transformational therapy for HFpEF patients.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs